Neonatal Fc Receptor in IgG-Mediated Autoimmune Disorders: Looking at a Common Denominator

(39:1econd)

What is FcRn and What Does It Do?

(1:18)

neonatal Fc receptor (English) - Medical terminology for medical students -

(39)

FcRn and the Long Half-Life of IgG Antibodies

(2:)

What is an FcRn Blocker and How Does It Work?

(1:3)

JAX Tech Talk #63: Let's talk FcRN: The Translational Platform for Antibody PK Assessment

(21:12)

FcRn model platform

(1:50)

The Role of FcRn In More Than 100 Autoimmune Diseases

(1:20)

About the FCRN

(1:16)

Neonatal Ventilation: Basics and Beyond Part 1

(1:22:53)

FcRn | 8/25 | UPV

(8:37)

Antibody Fc Engineering: Designing Antibodies for Cancer, Covid-19, and Beyond

(48:2)

Multiple Innovative Technologies \u0026 Platforms Empower Antibody Discovery

(1:3:44)

Neonatal Mechanical Ventilation (Quick Medical Overview)

(5:16)

Fab, Fc and F(ab')2 in antibodies (immunoglobulins) (FL-Immuno/36)

(6:33)

Neonatal Cerebral Function Monitoring (CFM)

(11:18)

Chimeric Antigen Receptor (CAR) / CAR-T

(5:52)

Advances in the Treatment of Myasthenia Gravis

(32:37)

4.2: Antibody Class

(13:3)

05/07/13 The Pacifying Effects of IVIG via FCγ Receptor

(2:19:17)

Advances in the Management of Immunoglobulin G-Mediated Autoimmune Diseases

(30:6)

Insights from ADVANCE IV study: efgartigimod increases platelet counts of patients with ITP

(52)

Impact of fcRn inhibitors on IgG-mediated autoimmune disorders

(45)

L59: How Your Baby Gets Immunity: The Science of Maternal Antibody Transfer of IgG1

(5:21)

cosMOG: anti-FcRn agent rozanolixizumab for relapse prevention in MOGAD

(1:32)

Results on Efgartigimod for Chronic Inflammatory Demyelinating Polyneuropathy Treatment

(6:23)

L4.2 Fc receptors structure and function

(12:49)

Journal Club | Anti-FcRn Treatment in Antibody-Associated Experimental Autoimmune Encephalomyelitis

(43:44)

FcRn Binding \u0026 Therapeutics Antibody Screening

(18:33)

Exploring the Efficacy and Evidence of Efgartigimod as a Potential Therapy for CIDP

(2:59)